Citation Impact
Citing Papers
Complement and microglia mediate early synapse loss in Alzheimer mouse models
2016 StandoutScience
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
2008
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
2013 Standout
Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR -Mutant Lung Cancer with and without T790M Mutations
2014
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2017
Introduction to the recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
2011
Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau
2015
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
2015
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
2005
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
2016 StandoutNature
The Dopamine Hypothesis of Drug Addiction: Hypodopaminergic State
2005
Apoptosis in the nervous system
2000 StandoutNature
Presenilins are essential for regulating neurotransmitter release
2009 StandoutNatureNobel
A view on drug resistance in cancer
2019 StandoutNature
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
2011 Standout
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases
2002 StandoutNature
Apolipoprotein E, Amyloid, and Alzheimer Disease
2002
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
2017
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Oxidative Damage Is the Earliest Event in Alzheimer Disease
2001 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Aβ oligomers inhibit synapse remodelling necessary for memory consolidation
2010
β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease
1996
Atomic structures of amyloid cross-β spines reveal varied steric zippers
2007 StandoutNature
Hippocampal Neuron Loss Exceeds Amyloid Plaque Load in a Transgenic Mouse Model of Alzheimer's Disease
2004
Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice
2014
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted β-amyloid precursor protein and mediates its degradation
1995
Dementia of the Alzheimer Type
2008
Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
2002 StandoutNature
Molecular aging of tau: disulfide‐independent aggregation and non‐enzymatic degradation in vitro and in vivo
2004
Alzheimer's Disease: The Amyloid Cascade Hypothesis
1992 StandoutScience
Tau in physiology and pathology
2015 Standout
What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?
1998 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Transgenic models of Alzheimer’s disease: Learning from animals
2005
Caspase activation precedes and leads to tangles
2010 Nature
ErbBs in lung cancer
2008
Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR Inhibitors
2005
Aβ peptides can enter the brain through a defective blood–brain barrier and bind selectively to neurons
2007
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
2006
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
2015
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
2009 Standout
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Tangles and plaques in nondemented aging and ?preclinical? Alzheimer's disease
1999
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Autoradiographic localization of dopamine D1 and D2 receptors in rat nucleus accumbens: Resistance to differential rearing conditions
1991 Standout
Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications
2006
Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation
2006 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins
2007
The Role of Apolipoprotein E in Alzheimer's Disease
2009
Alzheimer's Disease
2010 Standout
Neurotoxicity of Amyloid -Protein: Synaptic and Network Dysfunction
2012
Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases
2006 StandoutNature
In Vivo Imaging Reveals Dissociation between Caspase Activation and Acute Neuronal Death in Tangle-Bearing Neurons
2008
Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data
2015
Cell-Cycle Reentry and Cell Death in Transgenic Mice Expressing Nonmutant Human Tau Isoforms
2005
Enhanced Production and Oligomerization of the 42-residue Amyloid β-Protein by Chinese Hamster Ovary Cells Stably Expressing Mutant Presenilins
1997
Limbic Activation During Cue-Induced Cocaine Craving
1999
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
2008
Preclinical Evidence of Alzheimer Changes
2009
Tau phosphorylation in Alzheimer's disease: pathogen or protector?
2005
Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles
2014
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition
2017
The molecular neurobiology of depression
2008 StandoutNature
Molecular genetics of Alzheimer’s disease
2000
Single-cell transcriptomic analysis of Alzheimer’s disease
2019 StandoutNature
Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity
1999 StandoutNature
Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In Vivo
1996
Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer’s disease
2014
Pathways towards and away from Alzheimer's disease
2004 StandoutNature
Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer’s disease
2009
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
The molecular pathology of Alzheimer's disease
1991 Standout
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP
2010 StandoutNobel
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma
2007
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer
2006
The Amyloid Precursor Protein of Alzheimer's Disease in the Reduction of Copper(II) to Copper(I)
1996 Science
Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease
1997 Standout
Prion-inducing domain 2–114 of yeast Sup35 protein transforms in vitro into amyloid-like filaments
1997 StandoutNobel
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
2002 StandoutScience
EGFR Mutations in Non–Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening With Potential Implications on Pharmacologic Treatment
2005
MUTANT GENES IN FAMILIAL ALZHEIMER'S DISEASE AND TRANSGENIC MODELS
1998
Essential Role of BDNF in the Mesolimbic Dopamine Pathway in Social Defeat Stress
2006 StandoutScience
A Century of Alzheimer's Disease
2006 StandoutScience
IncreasedHER2Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients
2005
Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer
2005
Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
2015
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
2011
Targeting ALK: Precision Medicine Takes on Drug Resistance
2017
Aβ Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse
1997
GSK-3 is essential in the pathogenesis of Alzheimer's disease
2006
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
2015
Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease
2002
Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas
2006
Binding of F-spondin to amyloid-β precursor protein: A candidate amyloid-β precursor protein ligand that modulates amyloid-β precursor protein cleavage
2004 StandoutNobel
Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations
2006
APOE genotype and survival in men and women with Alzheimer’s disease
2002
Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer
2005
Alzheimer's Disease--Genotypes, Phenotype, and Treatments
1997 Science
Alzheimer's Disease Is a Synaptic Failure
2002 StandoutScience
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
2005 StandoutScience
Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
2004
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
2008
Cancer Genome Landscapes
2013 StandoutScience
Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib
2005
Casting Metal Nanowires Within Discrete Self-Assembled Peptide Nanotubes
2003 StandoutScience
Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models
1999
Amyloid precursor protein (APP) traffics from the cell surface via endosomes for amyloid β (Aβ) production in the trans -Golgi network
2012 StandoutNobel
Restoring E-Cadherin Expression Increases Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cell Lines
2006
Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process
2010
Apolipoprotein E ε4 allele, AD pathology, and the clinical expression of Alzheimer’s disease
2003
Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer
2005
ALZHEIMER'S DISEASE: Genetic Studies and Transgenic Models
1998
High-Level Neuronal Expression of Aβ1–42in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation
2000 Standout
First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study
2005
On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants.
1996
Differential Constitutive Activation of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cells BearingEGFRGene Mutation and Amplification
2007
MODELS OF AMYLOID SEEDING IN ALZHEIMER'S DISEASE AND SCRAPIE: Mechanistic Truths and Physiological Consequences of the Time-Dependent Solubility of Amyloid Proteins
1997
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2015
Normal development is an integral part of tumorigenesis in T cell-specific PTEN-deficient mice
2008 StandoutNobel
Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials
2005
The selective muscarinic M1 agonist AF102B decreases levels of total A? in cerebrospinal fluid of patients with Alzheimer's disease
2000
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
2012
Works of Howard West being referenced
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
2017
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
2007
Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease
1996
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
2014
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
1997
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
2015
CONDITIONED RELEASE OF NEUROTRANSMITTERS AS MEASURED BY MICRODIALYSIS
1992
Clinical and Neuropathological Correlates of Apolipoprotein E Genotype in Alzheimer's Disease ‐ Window on Molecular Epidemiologya
1996
Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126
2004
A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).
2010
Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study
2005
Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126)
2004
Increased EGFR gene copy number detected by fish is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126)
2005
Mutational analysis of K-RAS and EGFR implicates K-RAS as a resistance marker in the Southwest Oncology Group (SWOG) trial S0126 of bronchioalveolar carcinoma (BAC) patients (pts) treated with gefitinib
2005
Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline
2014
A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).
2015
Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).
2016
Bronchioloalveolar Carcinoma
2004
Phase II Trial of Irinotecan and Carboplatin for Extensive or Relapsed Small-Cell Lung Cancer
2009
Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome).
1995
A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761).
2015
Reduced apolipoprotein ϵ4 allele frequency in the oldest old Alzheimer's patients and cognitively normal individuals
1994